U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine

21-Sep-2009 - USA

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced that the U.S. food and Drug Administration (FDA) has approved the company’s supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.

The U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (H1N1) 2009 virus. Sanofi Pasteur provides the only influenza vaccine licensed in the U.S. for populations as young as 6 months of age and older.

“Obtaining FDA licensure of this vaccine for A (H1N1) pandemic response is a key milestone that will enable Sanofi Pasteur to provide a licensed vaccine to the U.S. government to support pandemic immunization efforts,” said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur.

Sanofi Pasteur is testing the immunogenicity and safety of its Influenza A (H1N1) 2009 Monovalent Vaccine through clinical trials, which began in the U.S. on August 6. Final data from these clinical trials will provide additional information to guide recommendations on the optimal dosage, number of doses and schedule. Similarly, clinical development activities with Sanofi Pasteur’s A (H1N1) vaccine manufactured in France are underway in close consultation with the European Authorities.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances